PT-141

What Is PT-141?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH). Unlike PDE5 inhibitors (Viagra, Cialis) that work peripherally on blood vessels, PT-141 acts centrally in the brain — specifically on melanocortin receptors (MC3R and MC4R) in the hypothalamus. This central mechanism produces sexual arousal from 'the inside out,' affecting desire rather than just physical blood flow.

PT-141 was FDA-approved in June 2019 as Vyleesi (bremelanotide injection 1.75 mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is taken as needed, approximately 45 minutes before anticipated sexual activity, via self-administered subcutaneous injection. It is the second FDA-approved medication for female sexual dysfunction (after flibanserin/Addyi).

In men, PT-141 is used off-label for erectile dysfunction and low libido, particularly in cases where PDE5 inhibitors are ineffective or contraindicated. The central mechanism means it can produce erections even in men with certain vascular conditions where Viagra fails. It has also been studied for sexual arousal in women beyond HSDD.

What The Research Says

Clinical trials supporting FDA approval demonstrated statistically significant improvements in satisfying sexual events and sexual desire scores in women with HSDD versus placebo. Pooled Phase 3 data showed approximately 1 additional satisfying sexual event per month — the key efficacy measure for approval.

In men, open-label and small controlled studies show erections in the absence of sexual stimulation, improved sexual function in men refractory to PDE5 inhibitors, and improved orgasmic function. The Central mechanism produces erections within 45-60 minutes typically.

📚 Key Reference: PMID: 31581961 (Phase 3 HSDD trial), PMID: 14626459 (early PT-141 study)

Common Uses

• Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved)
• Erectile dysfunction, especially refractory to PDE5 inhibitors (off-label)
• Sexual desire/libido in men (off-label)
• Female arousal disorder (off-label/investigational)

Important Safety Information

Most common side effects: nausea (40%), flushing (20%), headache. Nausea is dose-dependent and typically temporary. Blood pressure: PT-141 causes transient decreases in blood pressure — contraindicated with cardiovascular disease and use of nitrates, alpha-blockers, antihypertensives. Should not be used more than once every 24 hours. Skin hyperpigmentation with repeated use has been reported (due to MC1R activity). Do not use during pregnancy. Consult your provider.

Questions To Ask Your Provider

1. Is this the FDA-approved Vyleesi formulation or a compounded version?
2. For women: how is HSDD diagnosed and what alternatives were considered?
3. For men: why is this preferred over PDE5 inhibitors?
4. What cardiovascular screening should be done before use?
5. What are the strategies to reduce nausea?
6. How should this be stored and what is the injection technique?

Regulatory Status

FDA-approved as Vyleesi (bremelanotide 1.75 mg/0.3 mL injection) for HSDD in premenopausal women (AMAG Pharmaceuticals, June 2019). Compounded PT-141 is also available. Off-label use in men is common but not FDA-approved. Original nasal spray formulation (earlier) was not approved due to blood pressure concerns.